Vascular Solutions says US govt to intervene in off-label promotion probe
Aug 16 (Reuters) - Vascular Solutions Inc said the federal government would intervene in an investigation based on a former employee's allegations that company engaged in off-label promotion of its device to treat venous diseases.
The former employee's complaint, filed with the U.S. Attorney's Office for the Western District of Texas in November, 2010, alleged that the company's promotional practices cost the U.S. government about $20 million in damages.
Off-label promotion refers to the practice of prescribing a drug or a medical device for uses it has not been approved for by health regulators.
The complaint formed the basis of a June 2011 investigation brought by the attorney's office, under which the authority sought documents, particularly those related to Vascular Solutions' Vari-Lase Short Kit, which treats perforator veins.
The product has been selling in the United States since 2007 and had U.S. sales of about $410,000 through Dec. 31, 2011, contributing to less than 1 percent of the company's total U.S. sales, Vascular said in a regulatory filing.
"We have complied and we intend to continue to comply with the U.S. Attorney's investigation, but we're defending the litigation as something that's factually inaccurate and without merit," Chief Executive Howard Root told Reuters.
Shares of the Minnesota-based company were off 25 cents at $13.50 in Thursday afternoon trade on the Nasdaq.
- Malaysian plane presumed crashed; questions over false IDs |
- Malaysia signals missing plane has crashed; probes false IDs |
- CORRECTED-UPDATE 4-Malaysia Airlines plane crashes in South China Sea with 239 people aboard - report
- Libya threatens to bomb North Korean tanker if it ships oil from rebel port
- Malaysian jet's disappearance among rarest of aviation disasters